Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 30, 2011, Pages 12413-12418

  Khodoun, Marat V ^a,b   Strait, Richard ^a,c   Armstrong, Laura ^a,b   Yanase, Noriko ^a,b   Finkelman, Fred D ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Histamine; Mast cell; Platelet activating factor; Rodent

Indexed keywords

ANTIGEN; CD16 ANTIGEN; CHYMASE; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; PEANUT EXTRACT;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOPHIL; CELL CULTURE; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MARKER; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANAPHYLAXIS; ANIMALS; BASOPHILS; BIOLOGICAL MARKERS; CHYMASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTROPHILS; PEANUT HYPERSENSITIVITY; RECEPTORS, CELL SURFACE; RECEPTORS, IGG;

ARACHIS HYPOGAEA; MURINAE; MUS; RODENTIA;

EID: 79961078492     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105695108     Document Type: Article

References (44)

1. Simons FE (2010) Anaphylaxis. J Allergy Clin Immunol 125(2 Suppl 2):S161-S181.
2. Golden DB (2004) Patterns of anaphylaxis: Acute and late phase features of allergic reactions. Novartis Found Symp 257:101-110; discussion 110-115, 157-160, 276-285.
3. Strait RT, Morris SC, Finkelman FD (2006) IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc γ RIIb cross-linking. J Clin Invest 116:833-841. (Pubitemid 43326893)
4. Strait RT, Morris SC, Yang M, Qu XW, Finkelman FD (2002) Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 109:658-668. (Pubitemid 34327194)
5. Oettgen HC, et al. (1994) Active anaphylaxis in IgE-deficient mice. Nature 370:367-370. (Pubitemid 24259758)
6. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290. (Pubitemid 32368037)
7. Cheifetz A, et al. (2003) The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 98:1315-1324. (Pubitemid 36741529)
8. Wagner CL, et al. (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112:37-53.
9. Kolho KL, Ruuska T, Savilahti E (2007) Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 96:128-130.
10. Simons FE, et al. (2007) Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120(1 Suppl):S2-S24. (Pubitemid 46977436)
11. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D (1989) Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 83:1551-1555. (Pubitemid 19124110)
12. Schwartz LB (2004) Effector cells of anaphylaxis: Mast cells and basophils. Novartis Found Symp 257:65-74; discussion 74-79, 98-100, 276-285.
13. Lin RY, et al. (2000) Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol 106:65-71. (Pubitemid 30482854)
14. Simons FE, et al. (2008) Practical allergy (PRACTALL) report: Risk assessment in anaphylaxis. Allergy 63:35-37. (Pubitemid 350198250)
15. Hedin H, et al. (1980) Incidence, pathomechanism and prevention of dextran-induced anaphylactoid /anaphylactic reactions in man. Dev Biol Stand 48:179-189.
16. Umeda Y, et al. (2007) Anaphylactic shock related to aprotinin induced by antiaprotinin immunoglobulin G antibody alone; report of a case. Kyobu Geka, 60:69-71 (in Japanese).
17. Bergamaschini L, et al. (1995) Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: Role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 125:348-355.
18. Klastersky J (2006) Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Opin Oncol 18:316-320.
19. Cheifetz A, Mayer L (2005) Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 72:250-256. (Pubitemid 41052052)
20. Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10:301-316.
21. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317-327.
22. Campi P, Benucci M, Manfredi M, Demoly P (2007) Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists. Curr Opin Allergy Clin Immunol 7:393-403. (Pubitemid 47415282)
23. Khodoun M, et al. (2009) Peanuts can contribute to anaphylactic shock by activating complement. J Allergy Clin Immunol 123:342-351.
24. Kinet JP (1999) The high-affinity IgE receptor (Fc ε RI): From physiology to pathology. Annu Rev Immunol 17:931-972.
25. Khodoun MV, Orekhova T, Potter C, Morris S, Finkelman FD (2004) Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med 200:857-870. (Pubitemid 39362922)
26. Khodoun M, et al. (2007) Differences in expression, affinity, and function of soluble (s)IL-4Ralpha and sIL-13Ralpha2 suggest opposite effects on allergic responses. J Immunol 179:6429-6438.
27. Ohara J, Paul WE (1988) Up-regulation of interleukin 4/B-cell stimulatory factor 1 receptor expression. Proc Natl Acad Sci USA 85:8221-8225.
28. Armitage RJ, Beckmann MP, Idzerda RL, Alpert A, Fanslow WC (1990) Regulation of interleukin 4 receptors on human T cells. Int Immunol 2:1039-1045. (Pubitemid 20376756)
29. Dombrowicz D, et al. (1996) Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol 157:1645-1651. (Pubitemid 126449106)
30. Takizawa F, Adamczewski M, Kinet JP (1992) Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as Fc γ RII and Fc γ RIII. J Exp Med 176:469-475.
31. Unkeless JC (1979) Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580-596.
32. MacGlashan D, Jr., et al. (1994) Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 152:3006-3016.
33. Tsujimura Y, et al. (2008) Basophils play a pivotal role in immunoglobulin-G-mediated but not immunoglobulin-E-mediated systemic anaphylaxis. Immunity 28:581-589.
34. Dombrowicz D, et al. (1997) Absence of Fc epsilonRI α chain results in upregulation of Fc gammaRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between Fc epsilonRI and Fc gammaRIII for limiting amounts of FcR β and γ chains. J Clin Invest 99:915-925. (Pubitemid 27123628)
35. Brandt EB, et al. (2003) Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest 112:1666-1677. (Pubitemid 38063724)
36. Li XM, Schofield BH, Huang CK, Kleiner GI, Sampson HA (1999) A murine model of IgE-mediated cow's milk hypersensitivity. J Allergy Clin Immunol 103:206-214. (Pubitemid 29095823)
37. Leung DY, et al.; Avon Longitudinal Study of Parents and Children Study Team (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993. (Pubitemid 36302243)
38. Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc(γ)RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277-285.
39. Hazenbos WL, et al. (1998) Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol 161:3026-3032. (Pubitemid 28425728)
40. Finkelman FD, Morris SC (1999) Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol 11:1811-1818. (Pubitemid 29533096)
41. Finkelman FD, Morris SC, Orekhova T, Sehy D (2003) The in vivo cytokine capture assay (IVCCA) for measurement of in vivo cytokine production in the mouse. Curr Protoc Immunol Chapter 6:Unit 6.28.
42. Abrams JS, et al. (1992) Strategies of anti-cytokine monoclonal antibody development: Immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev 127:5-24.
43. Beckmann MP, et al. (1990) Monoclonal antibodies block murine IL-4 receptor function. J Immunol 144:4212-4217. (Pubitemid 20187759)
44. Miyajima I, et al. (1997) Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and Fc gammaRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1-dependent passive anaphylaxis. J Clin Invest 99:901-914. (Pubitemid 27123627)